Research on the Role of SLC1A5 in the Development of Esophageal Cancer

August 11, 2016 updated by: Fourth Affiliated Hospital of Guangxi Medical University

Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer

To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This will be an observational study. The investigators will aim to enroll 100 male and female adult patients (aged 18 years and over) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for esophageal cancer.

The investigators will be using a standardized data collection form. This is an observational study in which standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent. An attempt will be made to see if there is a correlation between the expression of SLC1A5 with esophageal cancer.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Zheng Peng
  • Phone Number: +86 18589966550
  • Email: labstar@qq.com

Study Contact Backup

  • Name: Shengming Dai, Dr.
  • Phone Number: +86 13978026884
  • Email: daishm@sina.com

Study Locations

  • China
    • Guangxi
      • Liuzhou, Guangxi, China, 545000
        • Recruiting
        • The Fourth Affiliated Hospital of Guangxi Medical University
        • Contact:
      • Liuzhou, Guangxi, China, 545000
        • Recruiting
        • Liuzhou Maternity and Child Healthcare Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with histologically proven esophageal cancer

Description

Inclusion Criteria:

  1. Patients with histologically proven esophageal cancer;
  2. Age ≥18 years;
  3. All patients must sign consent forms voluntarily;

Exclusion Criteria:

  1. Inability to obtain histologic proof of malignancy.
  2. Age <18 years;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
cancer tissues
SLC1A5 expression of esophageal cancer tissues from patients
Other: SLC1A5 expression
To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
paired adjacent tissues
SLC1A5 expression of paired adjacent esophageal tissues from patients
Other: SLC1A5 expression
To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
optical density (ODs) of each slice by immunohistochemistry assay
Time Frame: within one year (plus or minus 1 month) after surgery
For immunohistochemistry assay： Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field.
within one year (plus or minus 1 month) after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SLC1A5 expression detected by WesternBlot
Time Frame: within one year (plus or minus 1 month) after surgery
Western blot assay will be done by comparing the intensity of bands. To start with, xray film will be scanned on a flat-bed scanner. Then the grayscale image will be analyzed with software. Finally the Gray Value of each band will be obtained for analysis.
within one year (plus or minus 1 month) after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fourth Affiliated Hospital of Guangxi Medical University

Collaborators

Liuzhou Maternity and Child Healthcare Hospital

Investigators

  • Principal Investigator: Xiangcheng Wei, Guangxi Medical University Institutional Review Board

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2015

Primary Completion (Anticipated)

July 1, 2018

Study Completion (Anticipated)

August 1, 2018

Study Registration Dates

First Submitted

December 6, 2015

First Submitted That Met QC Criteria

December 14, 2015

First Posted (Estimate)

December 17, 2015

Study Record Updates

Last Update Posted (Estimate)

August 12, 2016

Last Update Submitted That Met QC Criteria

August 11, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PJK201518

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esophageal Cancer

Clinical Trials on SLC1A5 expression

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe